FMO1 as A Drug Target for Various Diseases (G2326)

Target Name: FMO1

NCBI ID: G2326

FMO1

FMO1 as A Drug Target for Various Diseases

FMO1, also known as Ovthump00000033537, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain.

Recent studies have suggested that FMO1 may be a drug target for various diseases, including Alzheimer's disease, Parkinson's disease, and cancer. This is because the blood-brain barrier is thought to be a key barrier to the delivery of many drugs, including those that are used to treat these diseases. By targeting FMO1, drugs may be able to bypass this barrier and reach the brain more effectively.

One of the potential benefits of targeting FMO1 is that it may be more effective than targeting other proteins, which may be targeted by drugs in the same way. This is because the blood-brain barrier is very selective, meaning that it is only open to certain substances. This makes it difficult for drugs to reach the brain, even if they are able to bind to a protein that is expressed there. By targeting FMO1 specifically, drugs may be able to bypass this barrier and deliver them more effectively to the brain.

Another potential benefit of targeting FMO1 is that it may be a more targeted approach to treating certain diseases. For example, Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells. There is currently no cure for Alzheimer's disease, and many treatments are only able to slow the progression of the disease and provide relief from symptoms. By targeting FMO1, drugs may be able to specifically target the protein and deliver it to the brain, rather than trying to target the disease itself.

FMO1 has also been suggested as a potential biomarker for certain diseases. By measuring the level of FMO1 in brain tissue, researchers may be able to diagnose and monitor the progression of certain diseases. For example, researchers may be able to use FMO1 levels as a biomarker to diagnose Alzheimer's disease, or to track the effectiveness of certain treatments.

In conclusion, FMO1 is a protein that is expressed in various tissues throughout the body, and it has been suggested as a potential drug target for various diseases. By targeting FMO1 specifically, drugs may be able to bypass the blood-brain barrier and deliver them more effectively to the brain. Additionally, FMO1 has also been suggested as a potential biomarker for certain diseases, which could be used to diagnose and monitor the progression of these diseases. Further research is needed to fully understand the potential of FMO1 as a drug target and biomarker.

Protein Name: Flavin Containing Dimethylaniline Monoxygenase 1

Functions: Broad spectrum monooxygenase that catalyzes the oxygenation of a wide variety of nitrogen- and sulfur-containing compounds including xenobiotics (PubMed:32156684). Catalyzes the S-oxygenation of hypotaurine to produce taurine, an organic osmolyte involved in cell volume regulation as well as a variety of cytoprotective and developmental processes (PubMed:32156684). In vitro, catalyzes the N-oxygenation of trimethylamine (TMA) to produce trimethylamine N-oxide (TMAO) and could therefore participate to the detoxification of this compound that is generated by the action of gut microbiota from dietary precursors such as choline, choline containing compounds, betaine or L-carnitine (By similarity)

The "FMO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FMO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets